David Glynn

David Glynn is an accomplished legal professional with extensive experience in the pharmaceutical and healthcare sectors. Currently serving as VP Legal and Chief Compliance Officer at Akebia Therapeutics since May 2024, David previously held the position of General Counsel for Commercial and Compliance at Krystal Biotech, Inc. from January 2022 to August 2023. Prior roles include Associate General Counsel at Ipsen, where oversight was provided for legal matters related to market access across oncology, neuroscience, and rare disease products, as well as an Assistant General Counsel and Partner at Holland & Knight LLP, advising on healthcare and compliance issues throughout the pharmaceutical supply chain. Earlier in his career, David practiced law at K&L Gates LLP and McKenna Long & Aldridge LLP. David Glynn earned a JD with honors from The George Washington University Law School and holds a BA in Political Science and Sociology from Franklin & Marshall College.